Hospital
Steward Sebastian River Medical Center, INC.
Steward Sebastian River Medical Center, INC. was paid $2.16M by Medicaid between Jan 2018 and Oct 2024, across 104 billing codes. Its largest line is 99283, emergency room visit (moderate) — 24% of everything it billed.
33Billing provider infoSTEWARD SEBASTIAN RIVER MEDICAL CENTER, INC.
SEBASTIAN, FL 32958
SEBASTIAN, FL 32958
33aNPI1619401528assigned 04/18/2017
33bProvider typeGeneral Acute Care Hospital
28Total paid$2.16M
24GClaims124,721
24DCodes billed104
24AFirst – last monthJan 2018 – Oct 2024
Compared with peers
Next to other General Acute Care Hospital providers in Florida
Rank by total paid#117 of 163
Median peer was paid$4.77M
This provider vs. median0.5×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official DOYLE, JOHN controls 13+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 11,044 | $137K | |
| 2019 | 23,879 | $344K | |
| 2020 | 23,355 | $298K | |
| 2021 | 31,250 | $471K | |
| 2022 | 25,008 | $541K | |
| 2023 | 8,691 | $282K | |
| 2024incomplete | 1,494 | $84K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 24% | 8,170 | 7,124 | $523K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 17% | 6,265 | 5,169 | $362K |
| 36415 | Collection of venous blood by venipuncture | 14% | 9,211 | 5,904 | $304K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 7.9% | 1,482 | 1,186 | $170K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 6.9% | 3,815 | 2,945 | $148K |
| 70450 | Computed tomography, head or brain; without contrast material | 4.4% | 935 | 749 | $95K |
| 96361 | Intravenous infusion, hydration; each additional hour | 3.2% | 2,103 | 1,626 | $69K |
| 80053 | Comprehensive metabolic panel | 2.8% | 7,716 | 5,682 | $59K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.5% | 599 | 529 | $33K |
| 81025 | 1.5% | 1,637 | 1,419 | $32K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.2% | 967 | 616 | $25K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 1.0% | 895 | 726 | $22K |
92 more codes
| 87081 | <1% | 1,078 | $21K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 340 | $17K |
| 71045 | Radiologic examination, chest; single view | <1% | 3,656 | $17K |
| 82947 | <1% | 599 | $17K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 187 | $17K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 2,112 | $15K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 2,000 | $14K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 3,560 | $14K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 9,114 | $14K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 743 | $13K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 328 | $10K |
| 81003 | <1% | 2,205 | $10K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 4,007 | $10K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 1,509 | $9K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 3,594 | $9K |
| J2704 | Injection, propofol, 10 mg | <1% | 2,270 | $8K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 101 | $7K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 378 | $7K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 397 | $7K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 28 | $6K |
| G0378 | Hospital observation service, per hour | <1% | 657 | $6K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 102 | $6K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 597 | $6K |
| 85610 | <1% | 2,681 | $5K | |
| 81001 | <1% | 2,595 | $5K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 2,129 | $4K |
| 84484 | <1% | 3,488 | $3K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 243 | $3K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 3,391 | $3K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 1,024 | $3K |
| 85730 | <1% | 1,615 | $3K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 3,622 | $3K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 1,302 | $3K |
| 83735 | <1% | 2,244 | $3K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 1,660 | $2K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 688 | $2K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 16 | $1K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 151 | $890.67 |
| 87040 | <1% | 87 | $882.51 | |
| 80305 | <1% | 341 | $869.92 | |
| 87807 | <1% | 148 | $825.83 | |
| 83690 | <1% | 1,472 | $824.24 | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 51 | $809.15 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,021 | $803.15 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 1,870 | $725.96 |
| 87186 | <1% | 470 | $712.05 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 296 | $662.59 |
| 00731 | <1% | 80 | $614.36 | |
| 87070 | <1% | 22 | $551.86 | |
| 85027 | <1% | 204 | $494.56 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,284 | $396.49 |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 336 | $358.04 |
| 84703 | <1% | 388 | $355.62 | |
| 80061 | Lipid panel | <1% | 405 | $331.58 |
| 86140 | <1% | 807 | $330.84 | |
| 97163 | <1% | 20 | $322.81 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 899 | $255.95 |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 515 | $254.31 |
| 83880 | <1% | 617 | $233.71 | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 234 | $221.23 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 103 | $142.12 |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 318 | $133.51 |
| 87205 | <1% | 22 | $127.58 | |
| 82962 | <1% | 356 | $50.87 | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 115 | $44.82 |
| G0237 | Therapeutic procedures to increase strength or endurance of respiratory muscles, face to face, one on one, each 15 minutes (includes monitoring) | <1% | 53 | $44.30 |
| 84439 | <1% | 14 | $42.67 | |
| 85651 | <1% | 33 | $21.08 | |
| 83605 | <1% | 266 | $16.50 | |
| 87400 | <1% | 13 | $15.30 | |
| 85379 | <1% | 328 | $15.04 | |
| 82607 | <1% | 21 | $13.20 | |
| 82746 | <1% | 16 | $7.47 | |
| 82150 | <1% | 143 | $2.95 | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | 0% | 156 | $0.00 |
| J1170 | Injection, hydromorphone, up to 4 mg | 0% | 376 | $0.00 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | 0% | 27 | $0.00 |
| 87088 | 0% | 34 | $0.00 | |
| 82550 | 0% | 32 | $0.00 | |
| 83615 | 0% | 13 | $0.00 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 0% | 16 | $0.00 |
| 82553 | 0% | 15 | $0.00 | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 0% | 62 | $0.00 |
| J0561 | Injection, penicillin g benzathine, 100,000 units | 0% | 15 | $0.00 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | 0% | 26 | $0.00 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | 0% | 46 | $0.00 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | 0% | 121 | $0.00 |
| 84145 | 0% | 49 | $0.00 | |
| 73610 | 0% | 13 | $0.00 | |
| 80076 | 0% | 118 | $0.00 | |
| 84600 | 0% | 15 | $0.00 | |
| 84702 | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialDOYLE, JOHN (CFO)
| Provider | Location | Paid |
|---|---|---|
| Steward ST. Annes Hospital Corporation | Fall River, MA | $82.71M |
| Steward Trumbull Memorial Hospital, INC. | Warren, OH | $16.49M |
| Steward Sharon Regional Health System, INC. | Sharon, PA | $6.76M |
| Steward Rockledge Hospital, INC. | Rockledge, FL | $6.16M |
| Southwest General Hospital LP | San Antonio, TX | $5.84M |
| Steward Sharon Regional Health System, INC. | Sharon, PA | $5.84M |
| SHC Youngstown Ohio Laboratory Services Company LLC | Poland, OH | $3.41M |
| Steward Melbourne Hospital, INC. | Melbourne, FL | $3.35M |
| Steward Hillside Rehabilitation Hospital, INC. | Warren, OH | $2.74M |
| Steward Northside Medical Center, INC. | Youngstown, OH | $1.58M |
| Steward Rockledge Hospital, INC. | Rockledge, FL | $974K |
| Newberry County EMS | Newberry, SC | $758K |
| Steward Sharon Regional Health System, INC. | Mercer, PA | $181K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.